Nephros (NEPH) Fundamentals 2026 — P/E 50.0x, Revenue Analysis | SniperIQ
Nephros (NEPH) is a US-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of $40M, trading at
Nephros (NEPH) is a US-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of $40M, trading at
Nephros (NEPH) has a market capitalization of approximately $40M, trading at
Nephros's trailing twelve-month P/E ratio is 50.0x, with a price-to-book (P/B) of 3.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Nephros runs a net profit margin of 4.1%, a gross margin of 59.1%, and an operating margin of 3.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Nephros reported revenue of
Nephros does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Nephros carries a debt-to-equity ratio of 0.09x and a current ratio of 4.55x, with a market beta of 1.49. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nephros (NEPH) the key facts are: market cap $40M, P/E 50.0x, revenue
Get Nephros's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.